241 related articles for article (PubMed ID: 32967342)
1. Cytokine Profiling in Myeloproliferative Neoplasms: Overview on Phenotype Correlation, Outcome Prediction, and Role of Genetic Variants.
Masselli E; Pozzi G; Gobbi G; Merighi S; Gessi S; Vitale M; Carubbi C
Cells; 2020 Sep; 9(9):. PubMed ID: 32967342
[TBL] [Abstract][Full Text] [Related]
2. Top advances of the year: Myeloproliferative neoplasms.
Bhave RR; Mesa R; Grunwald MR
Cancer; 2023 Dec; 129(23):3685-3691. PubMed ID: 37768996
[TBL] [Abstract][Full Text] [Related]
3. Platelet transcriptome identifies progressive markers and potential therapeutic targets in chronic myeloproliferative neoplasms.
Shen Z; Du W; Perkins C; Fechter L; Natu V; Maecker H; Rowley J; Gotlib J; Zehnder J; Krishnan A
Cell Rep Med; 2021 Oct; 2(10):100425. PubMed ID: 34755136
[TBL] [Abstract][Full Text] [Related]
4. Beyond JAK-STAT: novel therapeutic targets in Ph-negative MPN.
Gerds AT
Hematology Am Soc Hematol Educ Program; 2019 Dec; 2019(1):407-414. PubMed ID: 31808852
[TBL] [Abstract][Full Text] [Related]
5. MPNs as Inflammatory Diseases: The Evidence, Consequences, and Perspectives.
Hasselbalch HC; Bjørn ME
Mediators Inflamm; 2015; 2015():102476. PubMed ID: 26604428
[TBL] [Abstract][Full Text] [Related]
6. Circulating Cytokine Levels as Markers of Inflammation in Philadelphia Negative Myeloproliferative Neoplasms: Diagnostic and Prognostic Interest.
Mondet J; Hussein K; Mossuz P
Mediators Inflamm; 2015; 2015():670580. PubMed ID: 26525644
[TBL] [Abstract][Full Text] [Related]
7. Acute myocardial infarction in myeloproliferative neoplasms.
Manan MR; Kipkorir V; Nawaz I; Waithaka MW; Srichawla BS; Găman AM; Diaconu CC; Găman MA
World J Cardiol; 2023 Nov; 15(11):571-581. PubMed ID: 38058401
[TBL] [Abstract][Full Text] [Related]
8. ESTIMATE algorithm is not appropriate for inferring tumor purity and stromal and immune cell admixture in hematopoietic or stromal tumors.
Liu Q; Fang Y; Wang J
Cancer Immunol Immunother; 2020 Jun; 69(6):1153-1154. PubMed ID: 32152701
[No Abstract] [Full Text] [Related]
9. Longitudinal Cytokine Profiling Identifies GRO-α and EGF as Potential Biomarkers of Disease Progression in Essential Thrombocythemia.
Øbro NF; Grinfeld J; Belmonte M; Irvine M; Shepherd MS; Rao TN; Karow A; Riedel LM; Harris OB; Baxter EJ; Nangalia J; Godfrey A; Harrison CN; Li J; Skoda RC; Campbell PJ; Green AR; Kent DG
Hemasphere; 2020 Jun; 4(3):e371. PubMed ID: 32647796
[TBL] [Abstract][Full Text] [Related]
10. Myeloproliferative neoplasms - blurring the lines between cancer and chronic inflammatory disorder.
Soyfer EM; Fleischman AG
Front Oncol; 2023; 13():1208089. PubMed ID: 37361587
[TBL] [Abstract][Full Text] [Related]
11. Editorial: Megakaryocytes as regulators of tumor microenvironments.
Migliaccio AR; Balduini A; Zhan H
Front Oncol; 2022; 12():1090658. PubMed ID: 36505825
[No Abstract] [Full Text] [Related]
12. Cytokine Profiling as a Novel Complementary Tool to Predict Prognosis in MPNs?
Hasselbalch HC
Hemasphere; 2020 Jun; 4(3):e407. PubMed ID: 32647805
[No Abstract] [Full Text] [Related]
13. Remodeling the Bone Marrow Microenvironment - A Proposal for Targeting Pro-inflammatory Contributors in MPN.
Jutzi JS; Mullally A
Front Immunol; 2020; 11():2093. PubMed ID: 32983162
[TBL] [Abstract][Full Text] [Related]
14. Primary myelofibrosis: 2021 update on diagnosis, risk-stratification and management.
Tefferi A
Am J Hematol; 2021 Jan; 96(1):145-162. PubMed ID: 33197049
[TBL] [Abstract][Full Text] [Related]
15. The 2020 revision of the guidelines for the management of myeloproliferative neoplasms.
Kim SY; Bae SH; Bang SM; Eom KS; Hong J; Jang S; Jung CW; Kim HJ; Kim HY; Kim MK; Kim SJ; Mun YC; Nam SH; Park J; Won JH; Choi CW
Korean J Intern Med; 2021 Jan; 36(1):45-62. PubMed ID: 33147902
[TBL] [Abstract][Full Text] [Related]
16. Polycythemia vera and essential thrombocythemia: 2021 update on diagnosis, risk-stratification and management.
Tefferi A; Barbui T
Am J Hematol; 2020 Dec; 95(12):1599-1613. PubMed ID: 32974939
[TBL] [Abstract][Full Text] [Related]
17. Clinical insights into the origins of thrombosis in myeloproliferative neoplasms.
Moliterno AR; Ginzburg YZ; Hoffman R
Blood; 2021 Mar; 137(9):1145-1153. PubMed ID: 33237986
[TBL] [Abstract][Full Text] [Related]
18. The Hematopoietic Microenvironment in Myeloproliferative Neoplasms: The Interplay Between Nature (Stem Cells) and Nurture (the Niche).
Zhan H; Kaushansky K
Adv Exp Med Biol; 2020; 1273():135-145. PubMed ID: 33119879
[TBL] [Abstract][Full Text] [Related]
19. Heterogeneity of the bone marrow niche in patients with myeloproliferative neoplasms: ActivinA secretion by mesenchymal stromal cells correlates with the degree of marrow fibrosis.
Rambaldi B; Diral E; Donsante S; Di Marzo N; Mottadelli F; Cardinale L; Dander E; Isimbaldi G; Pioltelli P; Biondi A; Riminucci M; D'Amico G; Elli EM; Pievani A; Serafini M
Ann Hematol; 2021 Jan; 100(1):105-116. PubMed ID: 33089365
[TBL] [Abstract][Full Text] [Related]
20. Comparison and Implications of Mutational Profiles of Myelodysplastic Syndromes, Myeloproliferative Neoplasms, and Myelodysplastic/Myeloproliferative Neoplasms: A Meta-Analysis.
Wan Z; Han B
Front Oncol; 2020; 10():579221. PubMed ID: 33117717
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
